Defective HIV proviruses hinder immune system response and cure
Proteins created by defective forms of HIV long previously believed to be harmless actually interact with our immune systems and are actively monitored by a specific type of immune cell, called cytotoxic T cells, new evidence suggests. Ref. Source 9d.
On June 8, 2017, the U.S. Food and Drug Administration approved the first generic version of Truvada for the treatment of HIV-1, in combination with other antiretroviral agents, and for pre-exposure prophylaxis (PrEP) in combination with safer sex practices to prevent sexually-acquired HIV infection in adults at high risk.
PrEP may be part of a comprehensive HIV prevention strategy that includes safer sex practices, such as consistent and correct condom use, regular HIV testing and risk reduction counseling. As part of PrEP, HIV-uninfected individuals who are at high risk of sexually acquired HIV infection take antiretroviral medication daily to try to lower their chances of becoming infected with HIV if they are exposed to the virus.
The most common side effects reported by HIV-1 infected individuals using emtricitabine and tenofovir disoproxil fumarate in clinical trials included diarrhea, nausea, fatigue, headache, dizziness, depression, insomnia, abnormal dreams, and rash. HIV-1 uninfected individuals taking Truvada for PrEP reported headache, abdominal pain, and decrease of weight. Source 5j.
Molecule created that could 'kick and kill' HIV. Researchers have been looking for ways to eliminate the 'reservoirs' where the virus hides, and researchers may have developed a solution. Their approach involves sending an agent to 'wake up' the dormant virus, which causes it to begin replicating so that either the immune system or the virus itself would kill the cell harboring HIV. Source 2t.
HIV cell dysfunction discovery sheds light on how virus works. A new study has revealed that certain immune cells behave differently in HIV-infected patients than they do in healthy individuals, a discovery that moves us one step closer to understanding how the virus works. Source 4p.
High rate of viral suppression among people new to HIV care. Eighty-six percent of individuals who entered HIV care soon after diagnosis maintained viral suppression after 48 weeks during a clinical trial. Participants in the clinical trial, called iENGAGE, achieved viral suppression in an average of just 63 days. Source 8f.